Plexxikon, Wyeth ally in developing diabetes treatments
Wyeth Pharmaceuticals licensed exclusive development and marketing rights to Plexxikon's (small-molecule drug discovery) lead candidate PLX204 and other small-molecules that target peroxisome proliferator-activated receptors (PPARs) to treat metabolic disorders such as Type II diabetes.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.